AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Patients with informed consent to participate in the study.
Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
The applied immunotherapy should be the first or second line of treatment.
You may not be if
Patients who are unable to understand, read and / or sign informed consent.
Patients who can not collect stools.
Patients with fecal transplant.
The applied immunotherapy is not the first or second line of treatment.
Clareo Health | AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
